Two current and two former senior executives at AstraZeneca Plc are under investigation in China in an ongoing probe into alleged breaches of laws around drug importations and data privacy, the company said.

Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of senior executives in the company's China subsidiary have been implicated in an insurance fraud case.

(Reuters) -AstraZeneca shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior executives in China could be implicated in the largest insurance fraud case in the country's pharma sector in years.